Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ABL +25.2%, GDOT +18.6%, TMDX +18%, LASR +16.4%, GOGO +16.4%, DH +15.7%, TTD +14.5%, PINS +13.7%, LYFT +11.8% (also increases share repurchase program to $750 mln), MITK +11.8%, AMN +11.8%, MCHP +10.9%, PODD +10.9% (also authorizes new $125 mln share repurchase program), NET +10.5%, CARG +9.8%, FROG +9%, PUBM +9% (also increases share repurchase authorization by $100 mln), CBLL +8.9%, AMPX +8.8%, TOST +8.1% (also announces deal with Topgolf), CLFD +7.5%, TGS +7.1%, AVPT +7%, TWNP +6.9%, PSIX +6.3%, TMCI +5.8%, FNKO +5.7%, PRTA +5.5%, MNR +5.5%, ZD +5.2%, NGVC +5.1%, EVH +4.9%, ICUI +4.5%, TXG +4.4%, EVCM +4.3% (also increases share repurchase authorization by $50 mln), UI +4.2%, FOXF +3.8%, ALRM +3.6%, ANIP +3.5%, NTRA +3.3%, MTUS +3.1%, TREX +2.9%, AHR +2.8%, AFYA +2.8%, ATGE +2.7%, DIOD +2.7% (also authorizes new $100 mln share repurchase program), PGNY +2.7%, TSM +2.4% (April revs), SBSW +2.4%, TXNM +2.4%, CLNE +2.3%, MCK +2.2%, ROAD +2.2%, RXT +2.1%, VCTR +1.9%, FRT +1.9%, AGO +1.8%, DKNG +1.8%, TKO +1.8%, LPLA +1.8%, SLF +1.8% (also increases dividend), WEST +1.6%, KYMR +1.6%, ACLX +1.5%, EMBC +1.5%, TXRH +1.4%, RUM +1.3%, IMOS +1.3% (April revs), AQN +1.3%, IOSP +1.1%, DBX +1%, TU +1%
Other news:
- CRVS +34.9% (new interim data from phase 1 trial evaluating soquelitinib)
- PHX +20.1% (to be acquired by WhiteHawk Income)
- TLSA +4% (announces significant reduction in microglia activation in PET Scan of moderate Alzheimer's patient treated with intranasal foralumab)
- ICHR +3.8% (CEO buy shares)
- TERN +3% (files for $300 mln mixed securities shelf offering)
- CRMT +2% (names new CFO)
- AA +1.7% (names new non-executive Chairman)
- HRTG +1.3% (full placement of reinsurance program)
- AKRO +1.1% (Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin)